Results 211 to 220 of about 61,437 (248)

Antibody-drug conjugates as immuno-oncology agents in colorectal cancer: targets, payloads, and therapeutic synergies. [PDF]

Front Immunol
Wang Y, Lu K, Xu Y, Xu S, Chu H, Fang X.
europepmc   +1 more source

Design, synthesis and SAR of novel naphthalene-sulfonamide hybrids: anticancer assessment, gene expression analysis of IL6/JAK2/STAT3 signaling in MCF7 cells and antimicrobial evaluation. [PDF]

RSC Adv
Elsayed GH, Abdelazeem NM, Saleh AM, Abd El-Moez S, El-Hussieny M, Al-Ashmawy AAK.   +5 more
europepmc   +1 more source

Antibody drugs conjugates in small-cell lung cancer: present-day status and promises. [PDF]

Oncologist
Syal A, Meyer ML, Angelino K, Osei N, Gomez JE, Hirsch FR, Sen T.   +6 more
europepmc   +1 more source

Bispecific Antibody and Antibody-Drug Conjugate as Novel Candidates for Treating Pancreatic Ductal Adenocarcinoma. [PDF]

Biomolecules
Seo H, Go D, Jung SY, Han S, Nguyen VQ, Kwak M, Um W.   +6 more
europepmc   +1 more source

Antibody-Drug Conjugates and Beyond: Next-Generation Targeted Therapies for Breast Cancer. [PDF]

Cancers (Basel)
Wali AF, El-Tanani M, Talath S, Rabbani SA, Rangraze IR, Satyam SM, Avagimyan A, Hoffmann K, Ilias I, Ispas S, Viviana M, Paczkowska A, Rizzo M.   +12 more
europepmc   +1 more source

Antibody-Based Therapeutics in Breast Cancer: Clinical and Translational Perspectives. [PDF]

Antibodies (Basel)
Balata A, Pogoda K.
europepmc   +1 more source

Pharmacologic modulation of topoisomerase I inhibitors

, 2001
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

TOPOISOMERASE-I INHIBITORS IN GYNECOLOGIC TUMORS

Hematology/Oncology Clinics of North America, 1999
The first section of this article reviews recent studies that have clarified both the cellular role of topoisomerase I and the mechanisms of cytotoxicity of the topoisomerase inhibitors, the camptothecins. Different analogs of this new class of antitumor drug have been studied using various dose schedules in the treatment of refractory or recurrent ...
P, Haluska, E, Rubin, C F, Verschraegen
openaire   +2 more sources

Edotecarin: A Novel Topoisomerase I Inhibitor

Clinical Colorectal Cancer, 2005
Edotecarin (PHA-782615; formerly J-107088) is a derivative of NB-506, an indolocarbazole antitumor agent. It is a novel inhibitor of topoisomerase I that induces single-strand DNA cleavage more effectively than NB-506 or camptothecin (CPT) and at different DNA sequences. The DNA-topoisomerase I complexes induced by edotecarin are more stable than those
M Wasif, Saif, Robert B, Diasio
openaire   +2 more sources